TheraCryf (FRA:8EV) ROE % Adjusted to Book Value : -113.84% (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is TheraCryf ROE % Adjusted to Book Value?

TheraCryf's ROE % for the quarter that ended in Sep. 2023 was -63.75%. TheraCryf's PB Ratio for the quarter that ended in Sep. 2023 was 0.56. TheraCryf's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was -113.84%.

TheraCryf ROE % Adjusted to Book Value Historical Data

The historical data trend for TheraCryf's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf ROE % Adjusted to Book Value Chart

TheraCryf Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-9.66

-121.86

-20.82

-41.16

-42.90

TheraCryf Semi-Annual Data
	Mar13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-23.12	-38.97	-70.15	-48.33	-113.84

Competitive Comparison of TheraCryf's ROE % Adjusted to Book Value

For the Biotechnology subindustry, TheraCryf's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TheraCryf's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TheraCryf's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where TheraCryf's ROE % Adjusted to Book Value falls into.

TheraCryf ROE % Adjusted to Book Value Calculation

TheraCryf's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-53.63%	/	1.25
	=	-42.90%

TheraCryf's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-63.75%	/	0.56
	=	-113.84%

TheraCryf ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of TheraCryf's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

TheraCryf (FRA:8EV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

EVG:UK

Address

Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG

Website

https://www.evgen.com

Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (FRA:8EV) Headlines

No Headlines